Baseline characteristics of study participants
| Non-ischaemic cardiomyopathy (n=9) | Ischaemic cardiomyopathy (n=9) | Chemotherapy-induced cardiomyopathy (n=9) | P value | |
| Age (years) | 49.4±13.8 | 54.3±12.2 | 49.1±13.5 | 0.65 |
| Female | 77.8 | 77.8 | 77.8 | 1.0 |
| BMI (kg/m2) | 28.8±6.3 | 32.5±8.6 | 32.3±7.4 | 0.50 |
| LVEF | 22.8±7.3 | 27.0±7.0 | 29.8±10.6 | 0.23 |
| Hypertension | 55.6 | 77.8 | 66.7 | 0.87 |
| CAD | 0.0 | 100.0* | 11.1 | 0.001 |
| Diabetes | 11.1 | 77.8* | 22.2 | 0.02 |
| Atrial fibrillation | 0.0 | 22.2 | 22.2 | 0.50 |
| Sustained VT/VF | 0.0 | 0.0 | 0.0 | 1.0 |
| CVA | 11.1 | 33.3 | 22.2 | 0.84 |
| CKD | 11.1 | 11.1 | 11.1 | 1.0 |
| Smoking history | 66.7 | 66.7 | 0.0† | 0.006 |
| Medications | ||||
| Beta blocker | 100.0 | 100.0 | 88.9 | 1.0 |
| Statin | 33.3 | 88.9* | 44.4 | 0.05 |
| ACE-I/ARB | 88.9 | 88.9 | 66.7 | 0.57 |
| Digoxin | 33.3 | 33.3 | 44.4 | 1.0 |
| Antiarrhythmic | 0.0 | 11.1 | 0.0 | 0.35 |
Values are mean±SD or per cent.
*P< 0.05 comparing non-ischaemic versus ischaemic cardiomyopathy subjects.
†P<0.05 comparing non-ischaemic versus chemotherapy-induced cardiomyopathy subjects.
ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; CVA, cerebrovascular attack; LVEF, left ventricular ejection fraction; VF, ventricular fibrillation; VT, ventricular tachycardia.